The latest news, announcements and press releases from Chime Biologics.
（March 26,2021, Wuhan） Chime Biologics, a China-based, world-class CDMO company, announced today that it has secured a total commitment of US$190 million Series A+ investment from institutional investors in which over $100 million investment has already been closed today. This round financing was led by VMS Group and followed by Fidelity International and Panacea Venture. Earlier in February 2020 Chime Biologics has just completed its Series A financing of US$125 million.
This is the News section of the company profile page for Chime Biologics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.